News from the Sidney Kimmel Cancer Center: bullseye! Researchers nab the develop therapy for lethal leukemia.
Among cancer statistics, acute myelogenous leukemia (AML) ranks as the most common form of leukemia. But, with just over 10,000 cases per year, it is dwarfed by the lung, breast, prostate, and colon cancers that seem to monopolize media coverage, major scientific journal reports, and the attention
US DEPT OF HHS: Platinum-based chemotherapy for ovarian cancer carries increased risk of leukemia.
M2 PRESSWIRE-5 February 1999-US DEPT OF HHS: Platinum-based chemotherapy for ovarian cancer carries increased risk of leukemia - revised version (C)1994-99 M2 COMMUNICATIONS LTD RDATE:030299 A report in the Feb. 4 issue of the New England Journal of Medicine * Feb. 4, 1999. concludes that women
Fred Hutchinson Research Center Awarded $7 Million Grant To Lead Cancer Research Initiative; Investigation Is Part of The Leukemia & Lymphoma Society's $52 Million Global Research Program that Seeks to Find Cures for Blood Cancers.
WHITE PLAINS, N.Y. - The Leukemia & Lymphoma Society (the Society) announced it has awarded a $7 million grant through its Specialized Center of Research (SCOR) program to Dr. Irwin Bernstein, head of pediatric oncology research at the Fred Hutchinson Cancer Research Center in Seattle. Dr.
Cell Genesys Reports Encouraging Interim Results From Phase I Trial of GVAX Cancer Vaccine for Acute Leukemia.
FOSTER CITY, Calif. - Cell Genesys, Inc. today reported that a Phase I clinical trial of GVAX(R) cancer vaccine in patients with refractory or relapsed acute myelogenous leukemia (AML) and pre-leukemia has demonstrated clinical safety and the induction of antitumor immunity following GVAX(R)
The Leukemia & Lymphoma Society Honors Outstanding Contributors to Cancer Research and Patient Services.
CLEVELAND, Nov. 10 /PRNewswire/ - The Leukemia & Lymphoma Society awarded an international corporation and five individuals with prestigious awards that honor their significant contributions to the advancement of cancer research, improving the quality of life of patients and families. The
Scientists Using Gene Chips Identify Unique Form of Leukemia; Find Could Lead to Drugs for Lethal Infant Cancer.
Byline: Dana-Farber Cancer Institute BOSTON, Dec. 3 (AScribe Newswire) - Dana-Farber Cancer Institute scientists have discovered that a rare but lethal blood cancer that strikes infants in their first year is a genetically distinct type of leukemia that might someday be treatable with designer
"I CAME BACK FROM DEATH TO BE A CANCER CRUSADER".
After two excruciating bone-marrow transplants, 33-year-old Kim Tolnar thought her leukemia nightmare was over-until she discovered she was not the only one from her Ohio hometown stricken with cancer. * In 1992, the year I married my husband, Steve, I was a fun-loving, healthy 27-year-old. Our
The Leukemia & Lymphoma Society Honors Five Scientists for Outstanding Work in Blood Cancer Research.
WHITE PLAINS, N.Y., June 28 /PRNewswire/ - The Leukemia & Lymphoma Society has named five researchers as Stohlman Scholars, recognizing their outstanding contributions to the advancement of blood cancer research. The honors will be officially announced at the Society's Stohlman Scholar
Researcher at UCLA's Jonsson Cancer Center Wins Lifetime Achievement Award for His Efforts to Battle Leukemia.
Byline: UCLA LOS ANGELES, Oct. 1 (AScribe Newswire) - Renowned cancer researcher Dr. Owen Witte, who pioneered the research linking a mutant gene to chronic myeloid leukemia (CML), has won the Leukemia & Lymphoma Society's prestigious de Villiers International Achievement Award. The award, the
Cell Genesys Initiating Phase II Trial Of GVAX Cancer Vaccine for Acute Leukemia.
FOSTER CITY, Calif. - Cell Genesys, Inc. today announced that it is initiating a multicenter Phase II clinical trial of GVAX(R) cancer vaccine for acute myelogenous leukemia (AML), the most common form of adult leukemia. The trial will evaluate the safety and efficacy of GVAX(R) vaccine in
